Pancreatic Cancer Clinical Trials & Research at Providence Medical Group
Pancreatic cancer develops in the pancreatic ductal, acinar, and islet
cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal
(PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers
in the U.S. Risk factors that can be changed include tobacco use, obesity,
and workplace exposure to certain chemicals.
Providence Medical Group is currently enrolling patients for the following
pancreatic cancer clinical trial:
Study to Assess the ATR Kinase Inhibitor ART0380 Administered Orally as
Monotherapy and in Combination to Patients with Advanced or Metastatic
Solid Tumors